Lynx.MD partners with New York Gastroenterology Associates to advance real-world data in gastrointestinal research

The newly announced collaboration between Lynx.MD and the New York Gastroenterology Associates aims to foster increased gastrointestinal-related research and development.

Lynx.MD, a secure data network and medical intelligence platform specializing in the gastroenterology market, has announced a partnership with New York Gastroenterology Associates (NYGA), the largest independent gastroenterology practice in New York City, USA. An independent gastroenterology practice offering comprehensive expertise in gastrointestinal health, including inflammatory bowel disease and hepatology, NYGA will provide Lynx.MD with granular real-world data (RWD) to be securely integrated within the company’s research ecosystem to advance research and development.

Robert Eisdorfer, co-founder, Chief Medical Officer, and gastroenterologist at Lynx.MD, explained, "This partnership represents another step forward in our mission to revolutionize gastroenterology research. By combining NYGA's clinical expertise with Lynx.MD's advanced analytics, we are uniquely aligned to help life science, MedTech and biopharmaceuticals advance groundbreaking discoveries that will benefit patients worldwide."

NYGA actively engages in clinical research to further the development of new treatment approaches across a spectrum of gastrointestinal diseases. By collecting RWD and clinical insights, they also aim to enhance patient care and outcomes. Through the partnership, NYGA will enhance its research capabilities by leveraging the Lynx.MD data analytics platform, which integrates disparate data sources from across practice groups and platforms, providing comprehensive and actionable insights. As explained by David Hertz (Chief Operating Officer, NYGA):

"At New York Gastroenterology Associates we have a strong ethos to support research initiatives and drive innovation in the field of gastroenterology. Data can empower research and development of new treatments that help us deliver exceptional care to patients."